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Abstract: The integration of nanotechnology with biology has produced major advances in 
molecular diagnostics, therapeutics, and bioengineering. Recent advances have led to the devel-
opment of functionalized nanoparticles (NPs) that are covalently linked to biological molecules 
such as antibodies, peptides, proteins, and nucleic acids. These functionalized NPs allow for 
development of novel diagnostic tools and methods, particularly for pathogens, as rapid and 
sensitive diagnostics are essential for deﬁ  ning the emergence of infection, determining the period 
that preventive measures should be applied, for evaluating drug and vaccine efﬁ  cacy, and for 
controlling epidemics. In this study, we show that functionalized NPs conjugated to monoclonal 
antibodies can be used to rapidly and speciﬁ  cally detect respiratory syncytial virus in vitro and 
in vivo. These results suggest that functionalized NPs can provide direct, rapid, and sensitive 
detection of viruses and thereby bridge the gap between current cumbersome virus detection 
assays and the burgeoning need for more rapid and sensitive detection of viral agents.
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Introduction
Semiconductor quantum dots are excellent ﬂ  uorescent nanoprobes for biological and 
biomedical applications because of their unique size-dependent optical and electronic 
properties (Penn et al 2003; Alivisatos et al 2005; Hotz 2005). These nanoparticles 
(NPs) possess unique optical properties in comparison with traditional organic dyes 
including size- and composition-tunable emission, narrow emission spectra, and 
excellent photostability (Hotz 2005). Recent improvements in surface chemistry have 
augmented the ability to make functionalized NPs to create bioconjugated NPs that 
allow for speciﬁ  c targeting or signal enhancement (Farokhzad et al 2006; Fujiwara 
et al 2006; Goodman et al 2006; Ipe et al 2006; Suk et al 2006). Bioconjugated NPs, 
coupled with spectroscopy or other spectral imaging tools, eg, ﬂ  ow cytometry and 
histological techniques, provides a novel and powerful platform for mapping the 
molecular and disease proﬁ  les associated with infection by different pathogens (Zhao 
et al 2004; Driskell et al 2005; Yao et al 2006; McVeigh 2006). Another advantage of 
bioconjugated NPs over conventional pathogen detection methods is that the NPs may 
be conjugated with many biomolecules thereby enhancing the signal and the binding 
avidity by mitigating a multivalency effect. This is particularly important for targeting 
NPs and for increasing the delivery or efﬁ  cacy of bioconjugated molecules. However, 
only limited reports are available which address the utility of NPs for detection or 
diagnosis virus infection (Agrawal et al 2005, 2006; Bentzen et al 2005; Driskell et al 
2005; Li, Cu, et al 2005; Li, Liu, et al 2005; Wabuyele and Vo-Dinh 2005; Wan et al 
2005; Fuentes et al 2006; Liu, Cao, et al 2006; Souza et al 2006). 
Respiratory syncytial virus (RSV) is a single-stranded negative sense RNA virus 
in the Paramyxoviridae family that is the primary cause of morbidity and life-threat-
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ening lower respiratory tract disease in infants and young 
children worldwide, as well as an important pathogen of the 
elderly and immune compromised (Bader and McKinsey 
2005; Ebbert and Limper 2005; Mejias et al 2005) The dis-
ease burden associated with RSV infection is considerable 
as RSV is a leading cause of hospitalization for infants and 
young children worldwide having infection rates approaching 
70%–80% in the ﬁ  rst year of life with many patients requiring 
hospitalization (McCarthy and Hall 2003; Leung et al 2005). 
Unfortunately, despite ﬁ  ve decades of research, no safe and 
effective RSV vaccine is available and few effective prophy-
lactic or therapeutic treatments are available. Thus, there is a 
critical need for the development of novel tools and platforms 
to augment virus diagnosis and foundational studies required 
for development of disease intervention strategies.
The surface topography of viruses lends to detection by 
antibodies, a feature that has been successfully used for bio-
conjuagted NP detection of RSV (Agrawal et al 2005, 2006; 
Bentzen et al 2005). RSV has two major surface proteins, 
ie, G and F proteins, that are primarily responsible for virus 
attachment and fusion, respectively (Tripp 2005). Both G 
and F proteins are recognized by the immune system as neu-
tralizing antigens; thus a majority of antibodies are directed 
toward these proteins (Tripp 2005). The RSV F protein is 
more conserved than the G protein among RSV strains (Tripp 
2005), thus antibodies reactive to the F protein are ideal target 
developing bioconjugated nanoparticles. 
Taking advantage of the composition-tunable emission 
of NPs and their multivalent speciﬁ  city when conjugated to 
monoclonal antibodies, we tested the ability of these biocon-
jugated NPs to detect RSV infection in vitro and in vivo using 
in a single-step format. We show that bioconjugated NPs can 
be used to rapidly and sensitively detect RSV infection in 
both cell lines and mice, and that the detection can be done 
in a single step format. This single-step format dramatically 
improves virus detection time, potentially saves costs, and 
reduces background staining that is currently associated with 
conventional virus detection methods. 
Experimental procedures
Bioconjugated nanoparticles
To develop bioconjugated nanoparticles to detect RSV 
infection, semiconductor cadmium telluride (CdTe) quan-
tum dots (QDs) were synthesized as previously described 
(Wang et al 2002; Liu, Chen, et al 2006). QDs have been 
reported to be an excellent quantum particle for use in 
biological systems based on very high photoluminescence 
quantum efﬁ  ciencies, and the ability to cover the whole vis-
ible spectral range depending on particle size (Liu, Chen, 
et al 2006). Thus, two different sized CdTe Qds with emis-
sion peaks at 585 nm and 540 nm were prepared (Figure 1) 
and used in the preparation of bioconjugated nanoparticles 
(NPs) for detection of RSV infection. These particles were 
prepared for bioconjugation as previously described (Wang 
et al 2002), and conjugated to monoclonal antibodies reac-
tive to RSV F protein, clone 131-2A. Brieﬂ  y, thioglycolate 
(TGA)-coated CdTe particles were mixed 1:1 with RSV 
A.
B.
Figure 1 HRTEM images of green and orange CdTe nanoparticles showing an 
average size of 3 nm (A) and 5 nm (B), respectively.
Abbreviations: CdTe, cadmium telluride; HRTEM, high resolution transmission 
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anti-F protein monoclonal antibody (4 mg/ml) and the 
solution was stabilized with 10X phosphate-buffered saline 
(PBS), pH 7.2 to a ﬁ  nal 1 X PBS concentration. EDC/NHS 
(1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl/N-
Hydroxysulfosuccinimide) was added to bring to QD solution 
to a ﬁ  nal concentration of 50 mM/5mM, respectively. The 
reaction was incubated for 2 h at room temperature, then 
overnight at 4 °C. Precipitated bioconjugated NP aggregates 
were separated by centrifugation to remove unwanted ag-
gregates from single, bioconjugated nanoparticles. The ﬁ  nal 
concentration of the puriﬁ  ed NP-antibody conjugate stock 
solution was 0.625 mM. 
Vero cell and virus propagation
Vero cells (African green monkey kidney cells) were 
grown in Dulbecco’s Modiﬁ  ed Eagle’s Media (DMEM) 
containing 10% fetal bovine sera (DMEM-10%). For some 
experiments involving NPs, Vero cells were propagated 
on Lab-Tek chamber slides to 80%–90% conﬂ  uency using 
DMEM-10%.
Respiratory syncytial virus strain A2 (RSV) was propa-
gated in Vero cells as previously described (Tripp et al 1999). 
Brieﬂ  y, semi-conﬂ  uent Vero cells were prepared and washed 
with PBS. RSV was diluted in DMEM and the cells infected 
at a multiplicity of infection (MOI) of 1. The virus was al-
lowed to adsorb for 2 h at 37 °C after which DMEM-10% 
was added and the cells incubated at 37 °C for 4 days. At day 
4 post-infection (pi), the virus was recovered by removing 
the cell culture supernatant, freeze-thawing the infected cells, 
and centrifuging the cell lysate to remove debris and recover 
the virus from the cell lysate supernatant. 
Detection of RSV infection in vitro
The bioconjugated nanoparticles conjugated to anti-RSV F 
protein monoclonal antibody (RSV-NPs), ie, both 585 nm and 
540 nm QDs, were tested for their ability to detect RSV infec-
tion of Vero cells. RSV-infected Vero cells were propagated 
on Lab-Tek chamber slides to 80%–90% conﬂ  uency and 
subsequently infected with RSV at a MOI = 1 as previously 
described (Tripp et al 1999). At day 4 pi, the media from the 
cells was removed, the cells were washed gently with PBS, 
ﬁ  xed with acetone:methanol (60:40), and air dried. RSV-NPs 
(diluted 1:10,000) were added to the cells and incubated for 
1 hour at 37 °C, followed by three washes with PBS/0.05% 
Tween 20. Cells were visualized by ﬂ  uorescent microscopy 
(40X) on an Olympus CKX41 inverted microscope (Olym-
pus, Center Valley, PA), and photographed with an Olympus 
Q-Color3 digital camera. Images were analyzed using the 
Olympus Q-Capture software. 
The most widely used assay to quantitate virus titers in 
both the laboratory and clinical setting is the virus plaque 
assay. Virus plaques on the cell lawn are enumerated by 
immunostaining to speciﬁ  cally detect virus plaques due to 
confounding background staining that is often associated 
with the counterstain procedure. RSV-NPs were evaluated 
for detection of RSV infection using a modiﬁ  cation of 
an immunostaining plaque assay as previously described 
(Tripp et al 1999). Briefly, the modification involved 
substituting RSV-NPs in place of the primary (anti-RSV 
monoclonal antibody: clone 131-2A), secondary (anti-
mouse whole molecule immunoglobulin G (IgG)-alkaline 
phosphatase conjugated), and detection substrate, eg, Vec-
tor black alkaline phosphatase, to generate a single-step 
nanoparticle-based assay. In this modiﬁ  ed assay, Vero cells 
were plated onto 24-well ﬂ  at-bottom plates 24-h prior to 
RSV infection. Subsequently, the cell supernatants were 
removed and RSV diluted in DMEM was added to the 
cells at a MOI = 1. The virus was allowed to adsorb for 
1 h at 37 °C after which the cells were overlayed with 2% 
methylcellulose in DMEM-10% as previously described 
(Tripp et al 1999), and cells incubated for 6 days at 37 °C, 
5% CO2. At day 6 pi, the overlays were removed, and cells 
were ﬁ  xed with acetone: methanol (60:40), and allowed to 
air dry. Cells were blocked for 30 minutes with Powerblock 
(10% casein in PBS) at room temperature. RSV-NPs, either 
540 nm or 585 nm bioconjugated QDs, were diluted 1:1,000 
from 0.625 mM stock solution in PBS. For positive control 
wells, anti-RSV monoclonal antibody (clone 131-2A) was 
diluted 1:500 in PBS containing Powerblock, added to the 
appropriate wells, and incubated 1 hour for RSV-NPs, or 
2 hours for the primary monoclonal antibody at 37 °C. 
Cells were washed 3 times with PBS/0.05% Tween. For 
standard immunostaining plaque assay, secondary antibody 
(anti-mouse IgG-alkaline phosphatase conjugated) was 
diluted 1:500 in Powerblock, added to cells, incubated for 
1 hour at 37 °C, washed twice with PBS, and developed 
using a Vector black alkaline phosphatase substrate kit 
according to the manufacturer’s protocol. For RSV-NPs, 
the plates were directly scanned for virus plaques using 
an Amersham Biosciences Typhoon 9210 scanner with a 
ﬂ  uorescence excitation (532 nm) and emission (526 SP) 
ﬁ  lter. The virus plaques were enumerated and compared 
to plaque numbers obtained by standard counting using an 
Olympus SZ dissecting scope. International Journal of Nanomedicine 2007:2(1) 120
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Detection of RSV infection in vivo
To determine the ability of RSV-NPs to detect RSV infection 
in lung tissue, the natural site of RSV infection and replica-
tion (Tripp 2005), 6–8 week old female BALB/c mice were 
intranasally infected with 106 plaque-forming units (pfu) of 
RSV as previously described (Tripp et al 1999). At day 4 
pi, RSV-infected or naïve BALB/c mice were intravenously 
administered by tail vein 0.05 ml of RSV-NPs, either 540 
nm or 585 nm bioconjugated QDs, diluted 1:1000 in PBS 
from a 0.625 mM stock solution. At day 5 pi, the lungs from 
RSV-NP-treated or PBS carrier-treated mice were removed 
and prepared for thin sectioning and immunohistochemistry 
(IHC) analysis as previously described (Li, Sarmento, et al 
2005). Brieﬂ  y, lung tissue was frozen as tissue blocks and 
sectioned (20 μm) on a cryostat. The frozen sections were 
placed on slides which were immersed in acetone at 4 °C 
for 15 min, air dried for 30s, and then stored in PBS until 
immunostaining was performed. Brieﬂ  y, slides were stained 
with anti-RSV monoclonal antibody (clone 131-2A) diluted 
1:500 in PBS and incubated for 2 h at 37 °C. The slides were 
washed 2 times with PBS, and a secondary antibody (FITC 
conjugated anti-mouse IgG) diluted 1:500 in PBS was added 
to slides and incubated for 1 h at 37 °C, and washed twice 
with PBS. The lung sections from RSV-NP-treated mice and 
untreated mice that were immunostained as noted above were 
directly visualized using a ﬂ  uorescent microscope.
Results and discussion
Current antibody-based methods used for virus detection 
are cumbersome, have limited sensitivity due to substantial 
background staining, and are costly as they often require 
multiple antibodies and enzyme substrate for detection. In 
an effort to ameliorate these issues, and reduce the time for 
virus detection, we synthesized semiconductor CdTe QDs 
with emission at either 540 nm or 585 nm to be conjugated 
to monoclonal antibodies to detect RSV-infected cells. These 
bioconjugated NPs (RSV-NPs) that are speciﬁ  c to RSV F 
protein were tested for their ability to detect RSV infection 
of cells both in vitro and in vivo. As expected, no differ-
ences in virus detection were observed using either 540 or 
585 nm NPs.
As shown in the high resolution transmission electron 
microscopy (HRTEM) images in Figure 1, the green emis-
sion CdTe NPs had an average size of approximately 3 
nm (A) and the orange CdTe NPs of 5 nm (B). Given the 
reported difﬁ  culties conjugating proteins to CdTe NPs (Tan 
et al 2004; Gao et al 2005; McVeigh 2006), the CdTe NPs 
were produced with a thioglycolate coating to allow direct 
anti-RSV F protein monoclonal antibody conjugation via 
an EDC/Sulfo-NHS conjugation reaction. These bioconju-
gated NPs (RSV-NPs) were stable for >1 year at 4 °C, and 
did not precipitate in the PBS diluent at room temperature 
or at 4 °C. 
To determine the ability of the RSV-NPs to detect RSV 
infection, in vitro studies were performed using RSV-infected 
Vero cells. In these studies, we compared RSV detection 
using conventional antibody staining methods, ie, primary 
and secondary antibody staining plus enzyme substrate, 
to that of a single-step detection method using RSV-NPs. 
Conventional antibody staining methods produced sub-
stantial background staining in mock-infected Vero cells 
(Figure 2A), however did detect RSV plaque formation in 
the Vero cell lawn (Figure 2B). In contrast, RSV-NPs used 
in a single-step method produced little background (Figure 
2C), and readily detected RSV plaques (Figure 2D). These 
results show that RSV-NPs can be used to detect RSV in 
a single-step fashion, and that this method can be used to 
greatly reduce the amount of time and reagent needed for 
RSV detection compared to conventional immunostaining 
procedures (Tripp et al 1999).
Extending the in vitro detection ﬁ  ndings (Figure 2), we 
determined if RSV-NPs could be used to quantitate RSV 
titers in a single step fashion, thereby shortening the detec-
tion time needed to quantitate virus titers by plaque assay 
(Figure 3). In these studies, we compared a conventional 
immunostaining plaque assay which requires 5 or 6 days 
of in vitro culture post-RSV infection (Tripp et al 1999) to 
rapid single-step detection by RSV-NPs. For comparison of 
the different plaque assay methods, virus titers were assessed 
at days 2, 3, 5, or 6 pi. The results showed that at days 5 or 6 
pi, conventional immunostaining (Figure 3A) and the single-
step RSV-NP detection method (Figure 3B) were similarly 
sensitive for detecting RSV plaques in the Vero cell lawn. 
However, RSV-NPs could detect RSV plaques earlier (days 2 
or 3 pi) compared with conventional immunostaining which 
was comparatively ineffective (Figure 4), indicating that the 
single-step RSV-NPs procedure was more sensitive at detect-
ing limiting levels of RSV. This result is not unexpected 
given the multivalent properties of RSV-NPs. 
To evaluate the efﬁ  cacy of RSV-NPs to detect RSV 
infection in vivo, BALB/c were either intranasally 
infected with 106 pfu RSV or mock-treated, and at day 4 
pi, RSV-infected or mock-treated mice were intravenously 
administered 0.05 ml of RSV-NPs from the stock solution International Journal of Nanomedicine 2007:2(1) 121
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Figure 2 RSV-NP detection of RSV-infected Vero cells. Vero cells were mock-infected (A, C) or RSV-infected at a MOI = 1 (B, D) and ﬁ  xed with acetone: methanol (60:40). 
Cells were immunostained with by conventional methods (A, B) or by RSV-NPs (C, D), and analyzed using an immunoﬂ  uorescence microscopy (40X; A, C or 100X; B, D).
Abbreviations: MOI, multiplicity of infection; RSV-NP, respiratory syncytial virus-nanoparticles.
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Figure 3 RSV-NP virus plaque assay. RSV was serially diluted ten-fold and the dilutions used to infect Vero cells for determination of virus titers. The viral titer determined 
from a conventional immunostaining plaque assay (A). were compared with RSV-NPs detection (B). Both 540 nm and 585 nm QDs were evaluated as RSV-NPs (B). RSV 
plaques were enumerated using an Amersham Biosciences Typhoon 9210 scanner.
Abbreviations: RSV-NP, respiratory syncytial virus-nanoparticles; QDs, quantum dots.International Journal of Nanomedicine 2007:2(1) 122
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(0.625 mM) by tail vein. At day 5 pi, the lungs from RSV-
NP-treated or mock-treated mice were removed, frozen, 
and prepared for thin sectioning and IHC analysis using 
conventional methods, i.e. primary and secondary antibody 
staining, or directly visualized by ﬂ  uorescence microscopy 
in the case of RSV-NP treatment. Treatment with RSV-
NPs provided clear and rapid detection of RSV-infected 
lung tissue (Figure 5A) with very limited background 
staining as assessed in lung tissue from mock-treated mice 
similarly administered RSV-NPs (Figure 5B). Importantly, 
the magnitude and location of RSV-NPs staining along 
the epithelial cells of the alveoli in the lungs was similar 
to that of conventional IHC staining (Figure 5C), and the 
background staining for RSV-NPs was lower in naïve 
mice compared to conventional IHC staining (Figure 5D). 
The selective staining by RSV-NPs of only RSV-infected 
lung epithelial cells suggests antibody-mediated speciﬁ  c 
targeting to sites of infection. These results suggest that 
RSV-NPs may be useful to determine the progression of 
RSV infection in the lungs, and as a result, aid our under-
standing of sites of infection, and help to deﬁ  ne disease 
intervention strategies that employ bioconjugated NP 
targeting strategies.
Conclusions
The results from this study show that RSV-NPs can be used 
to detect RSV infection both in vitro and in vivo and suggest 
that beyond diagnostics, bioconjugated NPs may be useful for 
multiplexed detection of viral and/or host cell antigens, as well 
as for targeting sites of virus infection with antiviral agents that 
may be linked to the NPs. Indeed, bioconjugated NPs have 
been used to identify the presence and progression of RSV in-
fection in a human epithelial cell line, ie, HEp-2 cells (Bentzen 
et al 2005), as well as used in a variety of intracellular tracking 
and related studies (Alivisatos et al 2005; Bruchez 2005; Gao 
et al 2005; Hotz 2005; Shenoy et al 2006; McVeigh 2006). 
Figure 4 Dynamic range and sensitivity of detection of RSV-NP plaque assay compared with a conventional plaque assay. The viral titer of RSV-infected Vero cells was deter-
mined at day 3 pi (A) and day 5 pi (B) using conventional immunostaining plaque assay or single-step detection using 1:250 dilution of RSV-NPs derived from 585 nm QDs. 
RSV plaques were enumerated using an Amersham Biosciences Typhoon 9210 scanner.
Abbreviations: RSV-NP, respiratory syncytial virus-nanoparticles; QDs, quantum dots.
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Importantly, we show here that RSV-NPs can be applied as 
tools to enhance virus detection by increasing sensitivity of vi-
rus detection while decreasing the detection time. Application 
of RSV-NPs for virus detection in animal models can provide 
a path to assist our ability to dissect important parameters of 
RSV disease pathogenesis such as determining sites of virus 
infection and virus load in the lungs of infected animals. This 
understanding is critical to move the ﬁ  eld forward in antiviral 
disease intervention strategies.
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